Equillium (EQ) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Equillium (EQ) over the past year, gaining 40.0% versus a loss of 2.0%. Over five years, EQ leads with a -75.6% price change compared with -88.8% for PDSB. PDS Biotechnology is the larger company by market cap ($100.0 million vs $89.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EQ | PDSB |
|---|---|---|
| Share price | $1.41 | $1.38 |
| Market cap | $89.41M | $100.01M |
| 1-day change | -2.08% | +35.29% |
| YTD return | -7.10% | +79.22% |
| 1-year return | -2.04% | +39.96% |
| 5-year return | -75.63% | -88.81% |
| EPS (TTM) | $-0.14 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.54 | $1.55 |
| 52-week low | $0.76 | $0.195 |
| Distance from 52-week high | -60.17% | -10.97% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +507.09% | +262.32% |
| Average volume | 583.72K | 23.24M |
| Shares outstanding | 63.41M | 72.47M |
| Employees | 14 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed EQ by 42.0 percentage points over the past year.
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
EQ vs PDSB FAQ
Which is bigger, Equillium or PDS Biotechnology?
PDS Biotechnology (PDSB) is larger, with a market capitalization of $100.01M compared with $89.41M for Equillium (EQ).
Which stock has performed better over the past year, EQ or PDSB?
PDSB returned +39.96% over the past 12 months, compared with -2.04% for EQ (price return, excluding dividends). Past performance does not predict future results.
Are Equillium and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.